Pulmonary arterial hypertension leads to significant impairment in haemodynamics, right
heart function, exercise capacity, quality of life and survival. Current therapies have …

Balloon pulmonary angioplasty (BPA) is an emerging treatment option for patients with
chronic thromboembolic pulmonary hypertension (CTEPH) who have inoperable …

Objective Inoperable chronic thromboembolic pulmonary hypertension (CTEPH) managed
medically has a poor prognosis. Balloon pulmonary angioplasty (BPA) offers a new …

Care for patients with acute pulmonary embolism (PE) involves more than determination of
the duration of anticoagulant therapy. After choosing the optimal initial management strategy …

Background Balloon pulmonary angioplasty (BPA) has been demonstrated to improve
cardiac function and exercise capacity in patients with inoperable chronic thromboembolic …

Chronic thromboembolic pulmonary hypertension (CTEPH) is a complex chronic disease in
which pulmonary artery stenosis or obstruction caused by organized thrombus can lead to …

Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by recurrent or
unresolved pulmonary thromboemboli, leading to perfusion defects and increased arterial …

Background Diagnostic delay of chronic thromboembolic pulmonary hypertension (CTEPH)
exceeds 1 year, contributing to higher mortality. Health economic consequences of late …

Balloon pulmonary angioplasty (BPA) is a novel technique for the treatment of chronic
thromboembolic pulmonary hypertension. While cardiologists need no introduction to the …

Abstract Treatment options for chronic thromboembolic pulmonary hypertension (CTEPH)
that is not amenable to thromboendarterectomy or is recurrent/persistent after …